Heterocyclic compounds useful in the treatment of disease
Inventors
Beaton, Graham • Tucci, Fabio C. • RAVULA, SATHEESH B. • Shah, Chandravadan R. • LUU, Hiep
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
Heterocyclic compounds are described that are lysophosphatidic acid receptor ligands that are useful in the treatment of lysophosphatidic acid receptor-dependent diseases and conditions, including but not limited to diseases involving fibrosis, such as fibrosis of the heart, kidney, liver and lung, and scleroderma; inflammatory diseases such as diabetic nephropathy and inflammatory bowel disease; ocular diseases such as diseases involving retinal degeneration; nerve diseases such as pruritus and pain. Non-limiting examples of those compounds include (RS)-3-Cyclopropyl-2-{4-[3-methyl-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-benzyloxy}-propionic acid and (R)-1-(4′-{5-[1-(2-Chloro-phenyl)-ethoxycarbonylamino]-4-fluoro-pyrazol-1-yl}-2-fluoro-biphenyl-4-yl)-cyclopropanecarboxylic acid.
Core Innovation
The invention provides compounds having the structure of Formula I, or pharmaceutically acceptable salts thereof, including specific multi-ring arrangements defined by Ring A, Ring B, and the absence of Ring C. Ring A is a 5-membered heteroarene selected from defined options, Ring B is defined by corresponding ring options, and the structure includes R_A as —CO2H, with L1 as —UV—Z— and L2 absent.
Within Formula I, —UV— is defined by —WO—, —WN(RJ)—, or —C(=O)N(RJ)—, with W as C1-C3 alkylene and Z as C1-C6 alkylene, C3-C6 cycloalkylene, —C(RL)2—, or —CHR_L—. The structure further specifies substituent rules for R_C, R_D, R_E, R_F, R_G, CY, R_H, R_J, and R_L, including CY as substituted or unsubstituted C6-C10 aryl with substitution by 1, 2, or 3 independently selected R_H groups.
The disclosure describes lysophosphatidic acid (LPA) signaling via lysophosphatidic acid receptors (LPARs) as a target for treatment or prophylaxis of LPA-dependent diseases and conditions. Formula I compounds are provided as LPA/LPAR ligands that modulate LPAR-mediated signaling.
Claims Coverage
The supplied content includes independent claims centered on a Formula I compound, a method for treating a lysophosphatidic acid-dependent disease or condition, and a method for reducing signal transduction through a lysophosphatidic acid receptor (LPAR). The inventive coverage is anchored by the defined multi-ring Formula I scaffold, its fixed and variable substituent rules, and the use of that scaffold in LPA/LPAR-related methods.
Formula I compound with defined ring framework and substituent constraints
A compound having the structure of Formula I or a pharmaceutically acceptable salt thereof, wherein Ring A is a 5 membered heteroarene selected from specified heteroarene alternatives, Ring B is defined by specified ring system alternatives, Ring C is absent, R_A is —CO2H, L1 is —UV—Z— with —UV— defined by —WO—, —WN(RJ)—, or —C(=O)N(RJ)—, W is C1-C3 alkylene, Z is C1-C6 alkylene, C3-C6 cycloalkylene, —C(RL)2—, or —CHR_L—, and L2 is absent.
Permitted substituent patterns for RC, RD, RE, RF, RG, CY, R_H, R_J, and R_L
The Formula I compound wherein RC is selected from —F, —Cl, —Br, —I, —OC1-C4alkyl, C1-C4alkyl, C3-C6cycloalkyl, C1-C4fluoroalkyl, —CN, or —H; RD is selected from N(RF)C(=O)XCH2—CY, N(RF)C(=O)XCH(RG)CY, or N(RF)C(=O)XC(RG)2—CY with X as —O—; RE is —H or C1-C4alkyl; RF is —H or C1-C4alkyl; RG is C1-C4alkyl; CY is substituted or unsubstituted C6-C10aryl with substitution by 1, 2, or 3 independently selected R_H groups; each R_H is independently selected from —H, halogen, —OH, —ORJ, —SRJ, C1-C4alkyl, C1-C4fluoroalkyl, C1-C4fluoroalkoxy, and C1-C4alkoxy; each R_J is independently —H or C1-C6alkyl; and R_L is selected from the listed alkyl, heteroalkyl, fluoroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, and alkylene-linked variants.
Treatment of a lysophosphatidic acid-dependent disease or condition
A method for treating a lysophosphatidic acid-dependent disease or condition in a subject in need thereof by administering a therapeutically effective amount of a compound having the structure of Formula I or a pharmaceutically acceptable salt thereof.
Reducing signal transduction through a lysophosphatidic acid receptor
A method for reducing signal transduction through a lysophosphatidic acid receptor (LPAR) by contacting the LPAR with a compound having the structure of Formula I or a pharmaceutically acceptable salt thereof.
Across the independent claims, the inventive coverage is the same structurally defined Formula I scaffold, including Ring A selection, Ring B definition, Ring C absent, R_A as —CO2H, L1 as —UV—Z—, L2 absent, and the enumerated substituent rules. The method claims apply that scaffold to treating lysophosphatidic acid-dependent disease or condition and to reducing LPAR-mediated signal transduction.
Stated Advantages
Potency classification (A/B/C/D) is provided for representative compounds.
Receptor binding (LPA1R) potency is reported via [3H]-LPA displacement with IC50 and Ki values.
Functional antagonism is assessed via LPA1R calcium flux inhibition with antagonist IC50 values.
Documented Applications
LPA1R receptor binding assay using [3H]-LPA displacement in CHO-LPA1R cells, with IC50/Ki determination and scatchard plot support.
LPA1R calcium flux functional assay using FLIPR to determine antagonist IC50 values from inhibition of Ca2+ responses.
Treating a lysophosphatidic acid-dependent disease or condition in a subject in need thereof.
Organ fibrosis.
Nonalcoholic steatohepatitis (NASH), nephropathy, or diabetic nephropathy.
Reducing signal transduction through a lysophosphatidic acid receptor (LPAR).
Combination/co-administration with therapeutically active agents, including pioglitazone, statin drugs, chemokine receptor antagonists, selected mast cell stabilizers, and platelet activating factor receptor antagonists.
Interested in licensing this patent?